Alignment Healthcare, Inc. (NASDAQ:ALHC) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Alignment Healthcare, Inc. has received an average rating of "Moderate Buy" from eleven brokerages, with an average 12-month price target of $18.83.
• The company's recent earnings report showed a 49% year-over-year revenue increase to $1.02 billion, exceeding analyst expectations.
• Insider transactions included significant stock sales by both the CEO and a director, indicating a 10.39% reduction in their ownership stakes.

Alignment Healthcare, Inc. (NASDAQ:ALHC - Get Free Report) has received a consensus rating of "Moderate Buy" from the eleven brokerages that are presently covering the company, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $18.8333.

ALHC has been the topic of a number of research analyst reports. Zacks Research upgraded Alignment Healthcare to a "hold" rating in a research report on Friday, August 8th. KeyCorp raised Alignment Healthcare from a "sector weight" rating to an "overweight" rating and set a $21.00 price target for the company in a research note on Monday, August 25th. Stephens raised shares of Alignment Healthcare to a "strong-buy" rating in a research note on Monday, June 2nd. Wall Street Zen downgraded shares of Alignment Healthcare from a "buy" rating to a "hold" rating in a report on Sunday, August 10th. Finally, Barclays raised shares of Alignment Healthcare from an "underweight" rating to an "equal weight" rating and upped their price target for the company from $9.00 to $13.00 in a report on Thursday, July 31st.

Alignment Healthcare Price Performance

Shares of NASDAQ ALHC traded down $0.10 during midday trading on Friday, hitting $16.35. The company had a trading volume of 16,046,493 shares, compared to its average volume of 3,020,876. The firm has a market capitalization of $3.24 billion, a price-to-earnings ratio of -58.39 and a beta of 1.17. Alignment Healthcare has a twelve month low of $9.15 and a twelve month high of $21.06. The business has a 50-day simple moving average of $14.37 and a two-hundred day simple moving average of $15.49. The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 2.29.

Alignment Healthcare (NASDAQ:ALHC - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.14. Alignment Healthcare had a negative net margin of 1.53% and a negative return on equity of 43.68%. The company had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $960.25 million. During the same period last year, the company posted ($0.13) earnings per share. The firm's quarterly revenue was up 49.0% compared to the same quarter last year. Alignment Healthcare has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities research analysts anticipate that Alignment Healthcare will post -0.69 earnings per share for the current year.

Insider Activity at Alignment Healthcare

In other news, insider Robert L. Scavo sold 29,535 shares of the business's stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $16.41, for a total value of $484,669.35. Following the completion of the transaction, the insider owned 572,555 shares of the company's stock, valued at $9,395,627.55. The trade was a 4.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Joseph S. Konowiecki sold 25,000 shares of the firm's stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $17.00, for a total value of $425,000.00. Following the sale, the director owned 1,127,049 shares in the company, valued at $19,159,833. This trade represents a 2.17% decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,262,077 shares of company stock worth $19,805,859 over the last three months. Company insiders own 7.00% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ALHC. Amalgamated Bank boosted its position in Alignment Healthcare by 21.6% during the 1st quarter. Amalgamated Bank now owns 3,466 shares of the company's stock worth $65,000 after purchasing an additional 616 shares during the period. Tidal Investments LLC boosted its position in shares of Alignment Healthcare by 4.9% in the second quarter. Tidal Investments LLC now owns 18,094 shares of the company's stock worth $253,000 after buying an additional 852 shares during the period. Ballentine Partners LLC grew its stake in shares of Alignment Healthcare by 8.6% in the first quarter. Ballentine Partners LLC now owns 11,674 shares of the company's stock valued at $217,000 after buying an additional 924 shares in the last quarter. MCF Advisors LLC grew its stake in shares of Alignment Healthcare by 87.6% in the first quarter. MCF Advisors LLC now owns 2,165 shares of the company's stock valued at $40,000 after buying an additional 1,011 shares in the last quarter. Finally, Cresset Asset Management LLC raised its holdings in shares of Alignment Healthcare by 0.6% during the 1st quarter. Cresset Asset Management LLC now owns 287,565 shares of the company's stock valued at $5,354,000 after buying an additional 1,797 shares during the period. 86.19% of the stock is currently owned by hedge funds and other institutional investors.

About Alignment Healthcare

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.